Financing components and bundled warranty in device sales

Long installment sales and bundled service-type warranties on high-value medical devices are common in the distribution channel; failing to unbundle the financing component overstates device revenue and understates interest income over time, while misclassifying a service-type warranty as a simple cost provision defers revenue recognition incorrectly and can misstate margins on device sales for years.

Is the gap between device delivery and payment more than one year, and does that gap reflect a genuine financing arrangement rather than protection against non-performance or another business purpose? Does the extended warranty provide a service beyond assurance that the device works as specified, such as scheduled preventive maintenance visits, making it a distinct performance obligation? Is the standalone selling price of the maintenance/warranty component observable from separate sales, or does it need to be estimated?

1) For sales with deferred payment terms, assess whether the gap between delivery and payment exceeds roughly one year and, if so, whether the reason is a financing arrangement (versus another business purpose like non-performance protection). 2) If a significant financing component exists, split the contract consideration into a device sale component (recognized at the cash-equivalent selling price at the point control transfers) and a financing component (interest income recognized over the payment period using the effective interest method). 3) For extended warranties, assess whether they provide only assurance the device works as specified (an IAS 37 cost provision, not separate revenue) or an incremental service (e.g. scheduled preventive maintenance visits), which makes it a distinct performance obligation under IFRS 15. 4) For service-type warranties, allocate a portion of transaction price based on relative standalone selling price and recognize as revenue over the warranty coverage period as the service is delivered. 5) Apply the one-year practical expedient (no financing adjustment needed) only where the period between transfer and payment is genuinely one year or less. 6) Reassess the discount rate used for financing components only at contract inception, not subsequently, unless the contract is modified.

Discount the promised consideration using the rate that would be reflected in a separate financing transaction between the entity and the customer at contract inception (not the seller's general borrowing rate); allocate the transaction price between the device and the service-type warranty based on relative standalone selling prices, using observable prices for similar standalone maintenance contracts where available; recognize interest income/expense using the effective interest method over the financing period, separately presented from revenue from the sale of goods.

Disclose the practical expedient used, if the period between transfer of goods and payment is one year or less; disclose the amount of financing income/expense recognized in the period, presented separately from revenue from goods; disclose the policy for distinguishing assurance-type (IAS 37) from service-type (IFRS 15) warranties; disclose the allocation basis used for bundled service-type warranty consideration.

• Recognizing the full nominal sale price as revenue without discounting for a significant financing component on long installment terms, overstating device revenue
• treating an extended service-type warranty (with preventive maintenance visits) as a simple cost provision instead of deferred revenue, understating revenue and misstating its timing
• applying the financing component adjustment to short-term (under one year) credit terms unnecessarily, adding needless complexity
• using an inappropriate discount rate for the financing component (e.g. the seller'
• s own cost of borrowing instead of the rate reflective of a separate financing transaction with that customer).